Jazz Pharmaceuticals (JAZZ) Higher After Positive Analyst Ratings
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $252.16 -0.36%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) is seeing interest this morning on a couple positive ratings.
Barclays upgraded Jazz from Equalweight to Overweight and increased their price target from $12 to $15. In addition, Capstone Research initiated coverage on Jazz with a Buy rating and $11.50 price target.
Shares of JAZZ last traded at $8.50, up 5.5 percent.
Real-Time Market Moving News and Intelligence –Sign-Up Free Today
http://www.streetinsider.com/premium_content.php
Barclays upgraded Jazz from Equalweight to Overweight and increased their price target from $12 to $15. In addition, Capstone Research initiated coverage on Jazz with a Buy rating and $11.50 price target.
Shares of JAZZ last traded at $8.50, up 5.5 percent.
Real-Time Market Moving News and Intelligence –Sign-Up Free Today
http://www.streetinsider.com/premium_content.php
You May Also Be Interested In
- FOMC minutes from July 28-29th meeting
- Lyntris opens at $15.50, below IPO price of $17.50
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
Create E-mail Alert Related Categories
Insiders' Blog, New Coverage, Trader Talk, UpgradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
